Engineered immune cells take on tough lupus cases

NCT ID NCT07444307

Recruiting now Disease control Sponsor: Hangzhou Qihan Biotech Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests a new treatment called QT-019B for people with refractory systemic lupus erythematosus (SLE), a severe form of lupus that hasn't responded to standard therapies. The treatment uses specially engineered immune cells (CAR-T cells) from a healthy donor to target and attack faulty immune cells driving the disease. The main goals are to check safety and find the right dose, while also seeing if it can reduce lupus disease activity. About 18 to 24 adults aged 18 to 65 with refractory SLE can join.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

systemic lupus erythematosus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)

Contacts and locations

Locations

Peking Union Medical College Hospital
RECRUITING

Beijing, China
The First Affiliated Hospital of Ustc Anhui Provincial Hospital
RECRUITING

Hefei, Anhui, China
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
RECRUITING

Wuhan, Hubei, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.